Related Experiment Videos
Use of midazolam for refractory status epilepticus in pediatric patients
1Division of Child Neurology, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298-0211, USA.
Insights
Status epilepticus is more common in children. Midazolam effectively terminates refractory seizures in pediatric patients, offering a valuable alternative to traditional, more invasive treatments.
Area of Science:
- Pediatric Neurology
- Emergency Medicine
- Pharmacology
Background:
- Status epilepticus (SE) is more prevalent in children than young adults.
- While children may have better outcomes, SE can still cause significant neurological damage and sequelae.
- Prompt seizure termination is crucial for improving prognosis and reducing mortality in SE.
Purpose of the Study:
- To evaluate the efficacy of midazolam in treating refractory status epilepticus (RSE) in pediatric patients.
- To present midazolam as a valuable alternative to traditional RSE treatments.
Main Methods:
- Review of existing literature on status epilepticus treatment in pediatric populations.
- Analysis of midazolam's pharmacokinetic and pharmacodynamic properties.
- Comparison of midazolam's efficacy against conventional therapies for RSE.
Main Results:
- Conventional SE treatments (diazepam, lorazepam, phenytoin, phenobarbital) are effective in only 85-100% of cases.
- Refractory SE often requires barbiturate coma or general anesthetics, carrying significant risks and requiring intensive monitoring.
- Midazolam demonstrated high efficacy in terminating seizures refractory to first-line and second-line therapies in pediatric patients.
Conclusions:
- Midazolam is a highly effective and valuable treatment option for refractory status epilepticus in pediatric patients.
- Its favorable properties make it a preferred choice over traditional invasive methods for RSE.
- Midazolam offers a safer and more accessible approach to managing difficult-to-treat seizures in children.
Abstract:
Status epilepticus is more common among children than young adults. Children might be less likely to die and might be resistant to permanent neurologic damage due to status epilepticus, but significant sequelae also have been demonstrated. Aggressive intervention and rapid termination of seizures contribute significantly to better prognosis and reduced mortality from status epilepticus. Initial treatment of status epilepticus typically consists of either diazepam or lorazepam, immediately followed by phenytoin or phenobarbital. However, approximately 100% to 15% of status epilepticus episodes are refractory to these conventional therapies. Traditionally, refractory status epilepticus is treated with barbiturate coma or general anesthetics, both of which require invasive cardiorespiratory and hemodynamic monitoring and are associated with significant complications. Midazolam is a water-soluble benzodiazepine with a fast onset of action, a short half-life, and inactive metabolites that has been very effective in terminating seizures refractory to diazepam, lorazepam, phenytoin, and phenobarbital in pediatric patients. Midazolam is a valuable treatment option for refractory status epilepticus, especially in pediatric patients.